Equities researchers at HC Wainwright raised their FY2025 earnings per share estimates for shares of Integra Resources in a ...

Acumen Pharmaceuticals (NASDAQ:ABOS – Free Report) had its price target trimmed by HC Wainwright from $15.00 to $11.00 in a research note issued to investors on Friday,Benzinga reports. The brokerage ...

H.C. Wainwright keeps a Buy rating on Milestone Pharmaceuticals (MIST) after the company announced receipt of a complete response letter from the ...

Fintel reports that on March 27, 2025, HC Wainwright & Co. initiated coverage of RenovoRx (NasdaqCM:RNXT) with a Buy ...

H.C. Wainwright analyst Joseph Pantginis raised the firm’s price target on Aptose Biosciences (APTO) to $6 from $2 and keeps ...

H.C. Wainwright lowered the firm’s price target on Co-Diagnostics (CODX) to $1 from $1.50 and keeps a Neutral rating on the shares following ...

H.C. Wainwright lowered the firm’s price target on Acumen (ABOS) to $11 from $15 and keeps a Buy rating on the shares. The firm says completion ...

On Monday, H.C. Wainwright reaffirmed a Neutral rating on Shattuck Labs (NASDAQ: STTK) after the company released its fourth-quarter and full-year 2024 financial results. The biotechnology firm ...

On Friday, H.C. Wainwright reaffirmed its Buy rating and a price target of $11.50 on Innate Pharma (EPA:IPH) S.A. (NASDAQ:IPHA), representing significant upside from the current price of $1.97.

H.C. Wainwright analyst Mike Colonnese says the recent selloff in the bitcoin miners “has created a very attractive buying opportunity.” Macro factors will continue to overshadow positive ...

Fintel reports that on March 27, 2025, HC Wainwright & Co. initiated coverage of RenovoRx (NasdaqCM:RNXT) with a Buy recommendation. As of March 19, 2025, the average one-year price target for ...

On Friday, H.C. Wainwright reaffirmed its Buy rating and a price target of $11.50 on Innate Pharma (EPA:IPH) S.A. (NASDAQ:IPHA), representing significant upside from the current price of $1.97.